Aclarion Inc (ACON) USD0.00001

Sell:$7.22Buy:$8.10$0.13 (1.70%)

Prices delayed by at least 15 minutes
Sell:$7.22
Buy:$8.10
Change:$0.13 (1.70%)
Prices delayed by at least 15 minutes
Sell:$7.22
Buy:$8.10
Change:$0.13 (1.70%)
Prices delayed by at least 15 minutes

Company Information

About this company

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Key people

Jeff Thramann
Executive Chairman of the Board
Brent Ness
President, Chief Executive Officer, Director
John Lorbiecki
Chief Financial Officer
Ryan Bond
Chief Strategy Officer
William Wesemann
Lead Independent Director
David Neal
Director
Scott Breidbart
Independent Director
Steve Deitsch
Independent Director
Amanda Williams
Independent Director
Click to see more

Key facts

  • EPIC
    ACON
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6551874091
  • Market cap
    $4.48m
  • Employees
    6
  • Shares in issue
    582,371.00
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.